Home
Scholarly Works
Next Generation BTK Inhibitor Acalabrutinib with...
Conference

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Authors

Berinstein NL; Klein G; Welsh K; McClure R; Forward NA; Shafey M; Nikonova A; MacDonald D; Villa D; Sandhu I

Volume

140

Pagination

pp. 9383-9384

Publisher

American Society of Hematology

Publication Date

November 15, 2022

DOI

10.1182/blood-2022-169245

Conference proceedings

Blood

Issue

Supplement 1

ISSN

0006-4971

Contact the Experts team